ResearcherMoffitt Cancer CenterNo recent work listed

Yaman Suleiman

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5072203172. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2015: 1 paper

Papers 1

Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-015-2814-8 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gregory M. Springett · 1 shared paper, 2015 · strength 0.05
- Paper Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. DOI 10.1007/s00280-015-2814-8 ↗
Richard D. Kim · 1 shared paper, 2015 · strength 0.05
- Paper Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. DOI 10.1007/s00280-015-2814-8 ↗
Amit Mahipal · 1 shared paper, 2015 · strength 0.05
- Paper Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. DOI 10.1007/s00280-015-2814-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.